Here's Why BioCryst Pharmaceuticals Stock Is Losing Ground Today
Shares of BioCryst (NASDAQ: BCRX), a biopharmaceutical company, are falling after the company reported third-quarter earnings results. The FDA approved BioCryst's first drug, Orladeyo, for patients with hereditary angioedema last December. Independent new drug launches have a terrible tendency to miss expectations, so the stock market is extra jumpy about revenue figures right now.